Kurzfassung

A phase III, randomized, multicenter, open-label, comparative study to dthe efficacy of Durvalumab or Durvalumab and Tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease (Stage IV) Small-Cell Lung Cancer (SCLC)